Fluid Biomarkers: Revolutionizing MS Diagnosis

ReachMD CME
24/01/2025 5 min

Listen "Fluid Biomarkers: Revolutionizing MS Diagnosis "

Descargar episodio Ver en sitio original

Episode Synopsis

CME credits: 1.00
Valid until: 24-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/fluid-biomarkers-revolutionizing-ms-diagnosis/32229/



This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.

More episodes of the podcast ReachMD CME

Hepatic Encephalopathy: More Common Than You Think 11/12/2025
A Clear Horizon in Plaque Psoriasis: An Update on Investigational Oral Therapies 26/11/2025
Updates in Major Depressive Disorder with Insomnia 07/11/2025
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD 31/10/2025
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia 30/10/2025
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology 29/10/2025
Hepatic Encephalopathy: An Ominous Sign 23/10/2025
The Clinical Spectrum of Hepatic Encephalopathy 23/10/2025
Hepatic Encephalopathy: Tipping the Balance 23/10/2025
You Can’t Diagnose MHE Unless You Diagnose Cirrhosis 23/10/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA